Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: A basis for p53 haplo-insufficiency

Oncogene

Volumn 25, Issue 24, 2006, Pages 3463-3470

  Lynch, C J ^a   Milner, J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Haplo insufficiency; Li Fraumeni; mRNA; p53; SIRT1; Survivin

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; PROTEIN; PROTEIN P53; SURVIVIN;

ALLELE; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN HCT116; CLONE; DOWN REGULATION; HAPLOID INSUFFICIENCY; HAPLOIDY; HUMAN; HUMAN CELL; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS; UPREGULATION; WILD TYPE;

ALLELES; ANIMALS; GENE DOSAGE; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; LI-FRAUMENI SYNDROME; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PHENOTYPE; RNA, MESSENGER; SIRTUINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33745020716     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209387     Document Type: Article

References (49)

1. Allison S, Milner J. (2003). Cancer Res 63: 6674-6679.
2. Bean LJ, Stark GR. (2001). Oncogene 20: 1076-1084.
3. Bienz-Tadmor B, Zakhut-Houri R, Libresco S, Givol D, Oren M. (1985). EMBO J 4: 3209-3213.
4. Blagosklonny MV. (2000). FASEB J 14: 1901-1907.
5. Bode AM, Dong Z. (2004). Nat Rev Cancer 4: 793-805.
6. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y et al. (2004). Science 303: 2011-2015.
7. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. (1998). Science 282: 1497-1501.
8. Camplejohn RS, Perry P, Hodgson SV, Turner G, Williams A, Upton C et al. (1995). Br J Cancer 722: 654-662.
9. Cook WD, McCaw BJ. (2000). Oncogene 19: 3434-3438.
10. Deffie A, Wu H, Reinke V, Lozano G. (1993). Mol Cell Biol 13: 3415-3423.
11. de Moor CH, Meijer H, Lissenden S. (2005). Semin Cell Dev Biol 16: 49-58.
12. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J et al. (1994). Cancer Res 54: 1169-1174.
13. Espinosa JM, Emerson BM. (2001). Mol Cell 1: 57-69.
14. Espinosa JM, Verdun RE, Emerson BM. (2003). Mol Cell 12: 1015-1027.
15. Fojo T. (2002). Drug Resist Updat 5: 209-216.
16. Ford J, Jiang M, Milner J. (2005). Cancer Res 65: 10457-10463.
17. Freedman DA, Wu L, Levine AJ. (1999). Cell Mol Life Sci 55: 96-107.
18. Fu L, Ma W, Benchimol S. (1999). Oncogene 18: 6419-6424.
19. Geng L, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK et al. (2004). Nat Genet 36: 63-68.
20. Giannakou ME, Partridge L. (2004). Trends Cell Biol 14: 408-412.
21. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P et al. (1997). EMBO J 16: 1381-1390.
22. Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C et al. (2003). Nat Genet 33: 396-400.
23. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. (2002). J Biol Chem 277: 3247-3257.
24. Hofseth LJ, Hussain SP, Harris CC. (2004). Trends Pharmacol Sci 25: 177-181.
25. Hollstein M, Sidransky D, Vogelstein B, Harris CC. (1991). Science 253: 49-53.
26. Hu VW, Heikka DS, Dieffenbach PB, Ha L. (2001). FASEB J 15: 1562-1568.
27. Iwakuma T, Lozano G. (2003). Mol Cancer Res 1: 993-1000.
28. Kaeser MD, Iggo RD. (2002). Proc Natl Acad Sci USA 99: 95-100.
29. Komarova EA, Gudkov AV. (1998). Semin Cancer Biol 8: 389-400.
30. Latonen L, Laiho M. (2005). Biochim Biophys Acta 1755: 71-89.
31. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. (2001). Cell 107: 137-148.
32. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al. (2002). Oncogene 21: 2613-2622.
33. Mirzayans R, Pollock S, Scott A, Gao CQ, Murray D. (2003). Oncogene 22: 5562-5571.
34. Nemoto S, Fergusson MM, Finkel T. (2004). Science 306: 2105-2108.
35. Parant JM, Lozano G. (2003). Hum Mutat 21: 321-326.
36. Payne SR, Kemp CJ. (2005). Carcinogenesis 26: 2031-2045.
37. Rogel A, Popliker M, Webb CG, Oren M. (1985). Mol Cell Biol 5: 2851-2855.
38. Rubbi C, Milner J. (2003). EMBO J 22: 975-986.
39. Santarosa M, Ashworth A. (2004). Biochem Biophys Acta 1654: 105-122.
40. Soussi T, Lozano G. (2005). Biochem Biophys Res Commun 331: 834-842.
41. Varley JM, Evans DG, Birch JM. (1997). Br J Cancer 76: 1-14.
42. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D et al. (1998). EMBO J 17: 4657-4667.
43. Venkatachalam S, Tyner SD, Pickering CR, Boley S, Recio L, French JE et al. (2001). Toxicol Pathol 29(Suppl): 147-154.
44. Vogelstein B, Lane D, Levine AJ. (2000). Nature 408: 307-310.
45. Vousden KH. (2002). Biochim Biophys Acta 1602: 47-59.
46. Vousden KH, Lu X. (2002). Nat Rev Cancer 2: 594-604.
47. Waldman T, Kinzler KW, Vogelstein B. (1995). Cancer Res 55: 5187-5190.
48. Williams KJ, Boyle JM, Birch JM, Norton JD, Scott D. (1997). Oncogene 14: 277-282.
49. Yanokura M, Takase K, Yamamoto K, Teraoka H. (2000). Int J Radiat Biol 76: 295-303.